A Biomarker-directed Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy

Conditions

Lung

Phase II

Volunteers
Health Professionals

What is the purpose of this trial?

Phase 2 Platform Study in Patients with Advanced Non-Small Lung Cancer who progressed on First-Line Osimertinib Therapy. This study is modular in design, allowing evaluation of the efficacy, safety and tolerability of multiple study treatments.

Find out more about who can participate in this trial

Trial with
Astra Zeneca
Start Date
02/24/2020
End Date
11/10/2022

For more information about this study, contact:

Kira Fitzsimons Pavlik

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

Volunteer Now

Principal Investigator

Sarah Goldberg, MD, MPH
Associate Professor of Internal Medicine (Medical Oncology); Associate Director, Hematology/Oncology Fellowship Program

Sub-Investigators

Last Updated
10/21/2020
Study HIC
#2000025651

A Biomarker-directed Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy

Conditions

Volunteers

Health Professionals

What is the purpose of this trial?

I'm interested in volunteering

Principal Investigator

Sub-Investigators

Contact Information